Weak for, Strong for Additional references: Weak for Reviewed, New- replaced 8. For primary prevention in patients on moderate-dose statins, we suggest against maximizing the statin dose due to the lack of evidence proving added cardiovascular benefits and the risks of higher dose statins. Strong for [36,37,47,48,55- Additional references: Weak against Reviewed, New- replaced 9. For primary prevention, there is insufficient evidence to recommend for or against using ezetimibe with or without statins. Strong against [64] Additional references: Neither for nor against Reviewed, New- replaced 10. For primary prevention, we recommend against offering PCSK9 inhibitors due to unknown long-term safety, inconclusive evidence for benefit, and high cost. Not applicable [68,70-72] Additional references: Strong against Reviewed, New- added 11. For secondary prevention, we recommend using at least a moderate-dose statin. Strong for [49,56,74] Additional references: Strong for Reviewed, New- replaced 12. For secondary prevention in higher risk patients who are willing to intensify treatment, we suggest offering high-dose statins for reducing non-fatal cardiovascular events after discussion of the risk of high-dose statins and an exploration of the patient s values and preferences. Weak for [55-59,61,75-79] Additional references: Weak for Reviewed, New- replaced 13. For secondary prevention in higher risk patients who are willing to intensify treatment, we suggest adding ezetimibe to either moderate- or high-dose statins for reducing non-fatal cardiovascular events following a discussion of the risks, additional benefits, and an exploration of the patient s values and preferences. Weak for [75,76,80,81] Weak for Reviewed, New- replaced 14. 